|
Yellol J, Pérez SA, Yellol G, Zajac J, Donaire A, Vigueras G, Novohradsky V, Janiak C, Brabec V, Ruiz J. Highly potent extranuclear-targeted luminescent iridium(iii) antitumor agents containing benzimidazole-based ligands with a handle for functionalization. Chem Commun (Camb). 2016 Dec 1;52(98):14165-14168. PubMed PMID: 27869279.
AÑO: 2016; IF: 6.319
|
27869279
|
Zamora A, Denning CA, Heidary DK, Wachter E, Nease LA, Ruiz J, Glazer EC. Ruthenium-containing P450 inhibitors for dual enzyme inhibition and DNA damage. Dalton Trans. 2017 Feb 14;46(7):2165-2173. doi: 10.1039/c6dt04405k. PubMed PMID: 28121322.
AÑO: 2017; IF: 4.099
|
|
Wachter E, Zamora A, Heidary DK, Ruiz J, Glazer EC. Geometry matters: inverse cytotoxic relationship for cis/trans-Ru(ii) polypyridyl complexes from cis/trans-[PtCl2(NH3)2]. Chem Commun (Camb). 2016 Aug 9;52(66):10121-4. doi: 10.1039/c6cc04813g. PubMed PMID: 27352966; PubMed Central PMCID: PMC4980196.
AÑO: 2016; IF: 6.319
|
|
Zamora A, Pérez SA, Rothemund M, Rodríguez V, Schobert R, Janiak C, Ruiz J. Exploring the Influence of the Aromaticity on the Anticancer and Antivascular Activities of Organoplatinum(II) Complexes. Chemistry. 2017 Apr 24;23(23):5614-5625. doi: 10.1002/chem.201700717. Epub 2017 Mar 30. PubMed PMID: 28278370.
AÑO: 2017; IF: 5.16
|
|
Novohradsky V, Zamora A, Gandioso A, Brabec V, Ruiz J, Marchán V. Somatostatin receptor-targeted organometallic iridium(iii) complexes as novel theranostic agents. Chem Commun (Camb). 2017 May 17;53(40):5523-5526. doi: 10.1039/c7cc01946g. PubMed PMID: 28466888.
AÑO: 2017; IF: 6.29
|